Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 1(3)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03079531Phase 1Completed

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Role: lead

NCT03072485Phase 1Completed

Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers

Role: lead

NCT02690948Phase 1Completed

Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer

Role: lead

NCT02303041Phase 2Terminated

Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma

Role: lead

NCT01529450Not ApplicableCompleted

Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors

Role: lead

All 5 trials loaded